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A recent screen for compounds that selectively tar-
geted pancreatic cancer cells isolated UA62784.
We found that UA62784 inhibits microtubule poly-
merization in vitro. UA62784 interacts with tubulin
dimers ten times more potently than colchicine,
vinblastine, or nocodazole. Competition experiments
revealed that UA62784 interacts with tubulin at or
near the colchicine-binding site. Nanomolar doses
of UA62784 promote the accumulation ofmammalian
cells in mitosis, due to aberrant mitotic spindles, as
shown by immunofluorescence and live cell imaging.
Treatment of cancerous cell lines with UA62784 is
lethal, following activation of apoptosis signaling.
By monitoring mitotic spindle perturbations and
apoptosis, we found that the effects of UA62784
and of some known microtubule-depolymerizing
drugs are additive. Finally, high content screening
of H2B-GFP HeLa cells revealed that low doses of
UA62784 and vinblastine potentiate each other to
inhibit proliferation.
INTRODUCTION
Antimitotic drugs have long been used for the treatment of
cancers, and they usually target microtubules (MTs). Microtu-
bules are polymers composed of a/b-tubulin dimers, organized
in hollow cylinders whose dynamic instability is highly regulated.
In interphase, microtubules are essential to various processes
such as cell shape, vesicle transport, and cell signaling. Upon
mitotic entry, the nature and properties of microtubule-associ-
ated proteins dramatically switch to promote shorter and more
dynamic microtubules that will organize into a bipolar spindle.
This apparatus ensures alignment of the chromosomes at the
metaphase plate, a prerequisite for accurate chromosomes
partitioning in two identical sets (Gadde and Heald, 2004). This
step is subjected to a surveillance mechanism called the
‘‘spindle assembly checkpoint’’ which monitors attachment
and biorientation of kinetochores, and depends upon several
proteins, including the kinesin CENP-E and the kinase BubR1/
BUB1B (Mao et al., 2005; Weaver et al., 2003). Once chromo-Chemistry & Biology 18,somes are segregated, remodeling of the spindle microtubule
network results in the formation of the central spindle, a key
structure of the cytokinesis machinery.
The wide class of microtubule-targeting drugs is composed of
dozens of molecular backbones (Calligaris et al., 2010) interact-
ing with at least four tubulin binding sites: the taxane site, the
colchicine site, the vinca alkaloid site, and one or several
uncharacterized domain(s) (Smith and Jordan, 2010). Binding
to the taxane site stabilizes MTs. Vinca alkaloids and colchicine
are generally known asMT depolymerizing agents but it has also
been shown that at low, clinically relevant doses, they stabilize
MTs by decreasing microtubule dynamics (Jordan and Wilson,
2004; Okouneva et al., 2008). The mode of binding to tubulin
differs between the three main types of compounds. Taxanes
preferentially bind to polymerized MTs, at the inner surface of
the b subunit (Nogales et al., 1998). In contrast, colchicine binds
with high affinity to soluble tubulin but can become copolymer-
ized into MTs. Colchicine binding to b-tubulin prevents curved
tubulin from adopting a straight structure, due to a steric clash
between colchicine and a-tubulin, which inhibits MT assembly
(Ravelli et al., 2004). Finally, the vinca alkaloids generally bind
with high affinity to one or a few tubulin molecules at the tip of
MTs but do not copolymerize into MTs. Indeed, vinblastine
prevents self-association of tubulin by interacting at the interface
between two heterodimers (Gigant et al., 2005).
Vinca alkaloids such as vinblastine and vincristine are used in
clinics since the 1960s, mainly to treat leukemia and lymphomas
or certain advanced cancers. Their clinical efficiency in combina-
tion therapies motivated the development of semisynthetic
vinca analogs, including vindesine, vinorelbine, and vinflunine,
which are also efficient anticancer drugs. Taxol/paclitaxel and
its semisynthetic analog Docetaxel/Taxotere are also used as
chemotherapeutic agents to treat a wide variety of solid tumors.
Colchicine is not used for cancer treatment, probably due to high
levels of toxicity, but other molecules targeting the colchicine-
binding sites are under investigation for cancer treatment
(Jordan and Wilson, 2004).
There are several caveats with these treatments, which stimu-
late active research to keep developing alternatives (Screpanti
et al., 2010). Notably, the currently known drugs are still ineffi-
cient against several solid tumors, such as kidney, pancreas,
or colon carcinomas. During the last decade, novel antimitotics
targeting mitosis-specific enzymes such as protein kinases
(PLK1, Aurora) (Malumbres and Barbacid, 2007) and molecular
motors (Eg5/KIF11, CENP-E) (Wood et al., 2010) have been631–641, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 631
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Figure 1. UA62784 Does Not Affect the ATPase Activity of the Kinesin CENP-E
CENP-E ATPase activity was measured by following the release of ADP using the pyruvate kinase/lactate dehydrogenase–linked assay. The tests were per-
formed using three different constructs of CENP-E motor domain (MD): CENP-E-MD1-6His (A and D), CenpE-MD2-GFP-6His (B and E), and GST-CENP-E from
Cytoskeleton Inc. (C and F). Basal (A–C) and microtubule-stimulated (D-F) ATPase activities were measured and plotted as the percentage of the activity of the
motor in the absence of UA62784. Error bars represent the standard deviation from three independent experiments.
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UA62784, A Cytotoxic Inhibitor of Microtubulesdeveloped. Although some of these drugs are currently in
phase II clinical trials, none of them yet appeared to be as potent
as microtubule-targeting agents (Dumontet and Jordan, 2010;
Huang et al., 2009; Knox et al., 2008; Tang et al., 2008). Finally,
the search for novel compounds is also highly motivated by
the fact that many cancers eventually develop resistance to
these drugs (Kavallaris, 2010).
A recent screen for compounds that selectively targeted
pancreas cancer cells isolated UA62784 (Henderson et al.,
2009). UA62784 was found to be highly cytotoxic within nano-
molar range against human pancreatic cancer cell lines bearing
a deletion of the tumor suppressor gene dpc4 (deleted in
pancreas cancer locus 4). Henderson and colleagues attributed
the observed UA62784 action to CENP-E inhibition, and
UA62784 is being used at such in basic research studies (Maffini
et al., 2009). CENP-E is a molecular motor essential for chromo-
some congression, and for the spindle assembly checkpoint
(Abrieu et al., 2000; Weaver et al., 2003). It is also an attractive
drug target because its role is strictly restricted to mitosis
(Weaver et al., 2007). This prompted us to test UA62784 as
an inhibitor of CENP-E, but to our surprise, we found that
UA62784 does not inhibit CENP-E ATPase activity in vitro.
Strikingly, we found that UA62784 is a potent inhibitor of micro-
tubule polymerization, and we characterized its cytotoxicity,
alone or in combination with other known microtubule-targeting
agents, using live cell imaging and high content screening of
H2B-GFP HeLa cells. We found that UA62784 and vinca alkaloid
cytotoxicities are additive or even mildly synergic, which might632 Chemistry & Biology 18, 631–641, May 27, 2011 ª2011 Elsevierprovide a strategy to overcome resistance to known MT depoly-
merizing agents.
RESULTS
UA62784 Binds to Tubulin Dimers at or near
the Colchicine-Binding Site and Inhibits
Microtubule Formation
We used three constructs of human CENP-E motor domain to
measure its ATPase activity, in the presence (Figures 1A–1C)
or absence (Figures 1D–1F) ofmicrotubules.We could not detect
any inhibition of CENP-E ATPase activity, at any of five doses of
UA62784 ranging from 10 nM to 100 mM (Figure 1). Similar results
were obtained by measuring release of Pi instead of ADP (data
not shown). However, we found that UA62784 prevents microtu-
bule polymerization in MT pull-down experiments (Figure 2B). To
better quantify how UA62784 affects tubulin polymerization,
we monitored tubulin polymerization by following the increase
of the turbidity of the solution at 340 nm. UA62784 inhibits MT
polymerization in a dose-dependent manner (Figure 2C), with
a half-maximal inhibitory concentration (IC50) of 82 ± 20 nM
(Figure 2D).
We then investigated the ability of UA62784 to interact with
tubulin a/b dimers, using intrinsic tubulin tryptophan fluores-
cence as a probe (Figure 3A), in comparison with agents known
to directly interact with tubulin dimers such as vinblastine (Fig-
ure 3B), colchicine (Figure 3C), or nocodazole (Figure 3D). All
compounds induced a marked fluorescence quenching uponLtd All rights reserved
 Col  Ptx     0      2     50     100 
A 
C   
UA62784 (µM) 
S
P
O
N
O
O
UA62784
0,4
0 5 10 15 20 25 30 35 40
Paclitaxel (20nM)
Control (DMSO)
20 nM
200 nM
2000 nM
5000 nM
10000 nM
25000 nM
O
D
 (
3
4
0
 n
m
)
Time (min)
D  
B 
12.5 25 
UA62784 (µM) 
0 
P
o
l
y
m
e
r
i
z
e
d
 
T
u
b
u
l
i
n
 
(
%
)
 
100 
80 
60 
40 
20 
0 
IC
50
: 82 ± 20 nM 
0.1
0.2
0.3
Figure 2. UA62784 Inhibits Microtubule Polymerization
(A) Chemical structure of UA62784.
(B) Tubulin was polymerized for 5 min at 37C in the presence of the indicated
UA62784 concentrations. Colchicine (Col) (1 mM) and paclitaxel (Ptx) (1 mM)
were used as depolymerization and polymerization controls, respectively.
After sedimentation, the supernatant (S) and pellet (P) were analyzed by SDS
PAGE.
(C) Tubulin was polymerized for 40min at 37C in the presence of the indicated
concentrations of UA62784 and the absorbance at 340 nm was measured.
(D) The amount of polymerized tubulin in the presence of the indicated doses
of UA62784 was measured at 340 nm. Error bars represent the standard
deviation from three independent experiments. The concentration required for
half-maximal inhibition (IC50) is 82 ± 20 nM.
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Chemistry & Biology 18,binding to tubulin a/b dimers, as previously demonstrated for
colchicine and vinca alkaloids (Sackett, 1995), while paclitaxel,
which preferentially interacts with polymerized tubulin, did not
(data not shown). Steady-state fluorescence titrations are
biphasic and have been analyzed using a two binding site model:
a high affinity site with dissociation constant in the nanomolar
range (Kd1) and a low affinity site with dissociation constant in
the micromolar range (Kd2). Fitting of UA62784 titration curve
(Figure 3A) revealed a high affinity for tubulin with dissociation
constants for the first binding mode (Kd1) of 27 ± 13 nM and
for the second binding mode of 142 ± 104 mM (Kd2). Considering
that Kd2 is more than 5000-fold higher than Kd1, the second
binding mode can be negligible for UA62784. Kd1 values for
vinblastine (227 ± 45 nM), colchicine (324 ± 36 nM), or nocoda-
zole (259 ± 86 nM) indicated a roughly ten times lower affinity
of these drugs over UA62784 for tubulin. In contrast, affinity for
the second binding mode is 2- (vinblastin and Colchicine) to
8-fold (Nocodazole) higher than for UA62784, suggesting that
this second binding site should be taken into account for this
last compound. This was previously described for nocodazole
(Xu et al., 2002), and might reflect the presence of a mixture of
a/b isotypes in tubulin purified from porc brains (Banerjee and
Luduena, 1992).
In order to pinpoint UA62784 binding site, we performed
a competition experiment in the presence of [3H]-colchicine. As
shown in Figure 3E, the interaction of [3H]-colchicine with tubulin
is impaired by addition of increasing doses of UA62784. Addition
of 2 to 4 mM of UA62784 displaces more than 60% of the
[3H]-colchicine bound to tubulin, which is comparable to the
displacement achieved by 10 mM of colchicine. On the contrary,
even high doses of vinblastine do not alter the interaction of
[3H]-colchicine with tubulin. In conclusion, we found that
UA62784 directly interacts with tubulin heterodimers at or near
the colchicine-binding site, which affects the net amount of
polymerized tubulin in vitro.
UA62784 Arrests Mammalian Cells in Mitosis
and Promotes Apoptosis
To determine the effect of UA62784 in cellulo, we exposed
unsynchronized HeLa cells to increasing concentrations of
drug (ranging from 0.02 to 5 mM). The percentage of cells accu-
mulated in G2/M depended on the UA62784 concentration and
exposure time (Figure 4A). As shown in Figure 4A by flow cytom-
etry analysis, the cell cycle profile of HeLa cells after 12 or 24 hr
of treatment appears to be modified under 20 nM of UA62784.
Similar results were obtained with H358 cells (see Figure S1
available online). Quantification of the flow cytometry plots
show that 20 nM of UA62784 for 12 hr promotes the doubling
of the G2/M population from 21.5% ± 2.8% in untreated cells
to 40.1% ± 1.1% (Figure 4B). At the same time point, 57.7% ±
1.5% of the cells are in G2/M upon treatment with 200 nM of
UA62784 (Figure 4B). At later time points under 200 nM of
UA62784, the G2/M population culminates at 50.6% ± 2%
(24 hr) or 44.4% ± 1.6% (48 hr), concomitantly with an increase
in the sub-G1 population (Figure 4B).
Moreover, mitotic index, scored after staining with mitotic
protein monoclonal 2 (MPM2) antibody which recognizes pro-
teins sharing a mitosis-specific phosphorylated epitope, shifted
from 3%± 0.7% for untreated cells to 32% ± 4% for cells treated631–641, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 633
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Figure 3. UA62784 Interacts with Tubulin Heterodimers at or near
the Colchicine-Binding Site
Depolymerized tubulin was titrated with 15 nM to 75 mM of UA62784 (A),
vinblastine (B), colchicine (C), or nocodazole (D). Normalized fluorescence
quenching at 320 nm is fitted with a quadratic equation (see Experimental
Procedures). The corresponding dissociation constants are indicated. (E)
Tubulin (2 mM) was incubated with [3H]-colchicine (0.13 mM) in the absence of
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634 Chemistry & Biology 18, 631–641, May 27, 2011 ª2011 Elsevierwith 200 nM of UA62784 for 24 hr (Figure 4C). At this dose,
western blot analysis showed accumulation of mitotic markers
such as Cyclin B, phosphorylated histone H3, and MPM2 (Fig-
ure 4D). The persistence of phosphorylated BubR1/BUB1B in
this experiment strongly suggests that UA62784-treated HeLa
cells are delayed in mitosis due to activation of the spindle
assembly checkpoint (Figure 4D).
To examine how UA62784-treated cells eventually escaped
from this arrest, we checked for the presence of common effec-
tors of apoptosis by western blot. Activated caspase-3 and -9
and poly-ADP-ribose (PARP-1), were indeed all overexpressed
after 24 to 48 hr of UA62784 treatment (Figure 4E). This is consis-
tent with the appearance of increasing amounts of sub-G1 cells
upon 24–48 hr of treatment at doses of 20 nM and above
(Figure 4B).
To better characterize the effect of UA62784 in mitosis, we
stained UA62784-treated cells for tubulin by immunofluores-
cence and chromosomes with propidium iodide. Microscopy
analysis revealed three types of perturbed spindles (Figures 5A
and 5B). We define type I spindle as ‘‘aberrant but still bipolar,’’
type II as ‘‘multipolar,’’ and type III as ‘‘depolymerized.’’ The
occurrence of these phenotypes were scored for both HeLa
and H358 cells treated with UA62784 at concentrations ranging
from 20 to 80 nM for 8 hr. More than 70% of mitotic HeLa cells
treated with 20 nM of UA62784 display the ‘‘type II’’ phenotype,
while at 40 nM, 100%ofmitotic cells showno spindle (Figure 5C).
H358 cells are slightly more resistant to UA62784, but behave
similarly: more than 70% of the cells treated with 40 nM of
UA62784 have aberrant but still bipolar spindle, while 100% of
cells treated with 80 nM, have a depolymerized spindle (Fig-
ure 5D). Time-lapse video microscopy shows that microtubule
disruption upon UA62784 treatment occurs within minutes in
mitotic (Figure S2) and interphasic (Figure S3) HeLa cells.
Altogether, these results show that UA62784 is a potent inhib-
itor of microtubules polymerization both in vitro and in cellulo.
Cells treated with UA62784 arrest in mitosis and eventually die
by apoptosis.
The Effects of UA62784 Are Additive with Vinca
Alkaloids, Colchicine, or Nocodazole, but Not Paclitaxel
Since UA62784 is a novel microtubule inhibitor, we decided to
compare its effect in mitosis on human cells with the effect of
other well-characterized microtubule-targeting agents, such as
nocodazole, colchicine, vinblastine and paclitaxel. Meanwhile,
we investigated whether the effect of UA62784 in mitosis could
be additive with these other drugs. G1/S synchronized HeLa
cells were incubated with various drugs either alone or in combi-
nation with UA62784 for 12 hr. Figure 6A shows the representa-
tive mitotic phenotypes observed by immunofluorescence and
Figure 6B display the quantification of these data. In agreement
with Figure 5, treatment with 20 nM of UA62784 induces the
appearance of perturbed but still bipolar spindles in a majority
of cells. However, at this dose of UA62784, further addition ofdrug (ctrl), or presence of colchicine (10 mM), vinblastine (20 mM), or increasing
concentrations of UA62784 (0.125; 0.25; 0.5; 1; 2 and 4 mM). The amount of
[3H]-Colchicine bound to tubulin was determined as described in Experimental
Procedures. Error bars represent the standard deviation from three indepen-
dent experiments.
Ltd All rights reserved
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Figure 4. UA62784 Delays HeLa Cells in Mitosis and Promotes Apoptosis
(A) HeLa cells were exposed to the indicated concentrations of UA62784 for 12, 24, and 48 hr and analyzed by flow cytometry.
(B) Quantification of the percentage of cells in Sub-G1, G1, S, and G2/M phases by flow cytometry. (circle) Sub-G1; (square) G1; (triangle) S; (diamond) G2/M.
(C) HeLa cells treated with the indicated concentrations of UA62784 for 12, 24, and 48 hr were fixed with methanol, stained with PI andMPM2-FITC and analyzed
by flow cytometry. The average mitotic index of three independent experiments was plotted.
(D) HeLa cells were treated with 200 nM of UA62784 for 12, 24, 48, and 72 hr and the level of the indicated proteins in cell lysates was analyzed by western blot.
Actin was used as a loading control.
(E) Activation of apoptotic markers upon UA62784 treatment. HeLa cells were treated with 200 nM of UA62784 for 12, 24, 48, and 72 hr, and the level of activated
caspase-3, caspase-9, and PARP were analyzed in cell lysates by western blot.
See also Figure S1.
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UA62784, A Cytotoxic Inhibitor of Microtubulesnocodazole (10 nM) or vinblastine (6 nM) promotes the more
severe type III phenotype. Addition of colchicine (1.5 nM) also
raises the severity of the mitotic phenotypes induced by
UA62784 alone (Figure 6B), while addition of paclitaxel (1.5 nM)
does not. Reciprocally, the severity of the mitotic phenotypesChemistry & Biology 18,induced by nocodazole, colchicine, or vinblastine, but not pacli-
taxel is worsened by concomitant addition of UA62784. We also
followed the fate of the treated cells by flow cytometry in order to
quantify the increase in the sub-G1 population, a hallmark of
apoptosis (Figure S4). This second readout also shows that the631–641, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 635
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Figure 5. UA62784 Perturbs the Mitotic Spindle
HeLa (A andC) andH358 (B and D) cells were treatedwith lowUA62784 concentrations for 8 hr, fixed, stainedwith anti-b-tubulin antibody (green) and PI (red), and
imaged by fluorescence microscopy (A and B). The ratio of three types of aberrant mitotic phenotypes (see text) was plotted (C and D).
See also Figures S2 and S3. Error bars represent the standard deviation from three independent experiments.
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UA62784, A Cytotoxic Inhibitor of Microtubuleseffects of UA62784 and of the three other microtubule-depoly-
merizing drugs tested are additive, which is not the case with
the microtubule-stabilizing agent paclitaxel.
Third, we analyzed how UA62784 alone, or in combination
with other drugs, affected cell viability. In this experiment, we
included doxorubicin, a DNA intercalant irrelevant to microtu-
bules. To this end, we seeded 96-well plates with equal number
of HeLa-H2B-GFP expressing cells to count the number of living
cells every 24 hr over 4 days. Each drug was tested alone at six
different doses. This allowed us to calculate the dose that inhibits
half of the cells growth (IG50). Figure 7A shows that the dose of
UA62784 or nocodazole required to kill half of the cells is in the
same range (30 nM) and similar to vinblastine (14 nM), while
there is roughly a factor ten of difference, down for paclitaxel
(1.7 nM) or up for doxorubicin (240 nM) in the same condi-
tions. The results from three different fields in the same well636 Chemistry & Biology 18, 631–641, May 27, 2011 ª2011 Elsevierallowed us to draw theoretical additive lines between UA62784
and the other drugs tested (Figure 7B; Table S1), to perform
isobolographic analysis of drug combinations. We also com-
bined UA62784 with any one of the other drugs, using three
couples of doses, and calculated the corresponding IG50. The
results are displayed in Figure 7C and are spotted on the isobolo-
graphic graphs in Figure 7B. This shows that cytotoxicity
induced by UA62784 and nocodazole or vinblastine is additive,
or even mildly synergistic, while ua62784 antagonizes pacli-
taxel-induced cell death.
DISCUSSION
In the present study, we have carried out an in-depth character-
ization of the effect of UA62784 as a potent inhibitor of micro-
tubule polymerization both in vitro and in cellulo. Furthermore,Ltd All rights reserved
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Figure 6. UA62784 and Nocodazole (noc), Colchicine (Col), and
Vinblastine (Vbl), but Not Paclitaxel (Ptx) Potentiate Each Other to
Perturb the Mitotic Spindle
(A) Representative images of HeLa cells synchronized by Thymidine for 24 hr
and released in the presence of the indicated concentration of drugs alone, or
in combination for 12 hr. After fixation, the cells were stainedwith anti-b-tubulin
(green), anti-g-tubulin (blue) antibodies, and PI (red) and imaged by micros-
copy.
(B) The ratio of normal versus three types of aberrant mitotic phenotypes (see
text and Figure 5) from the same experiment is plotted. Three doses of
UA62784 (0; 10; 20 nM) are used alone or in combination with nocodazole
(10 nM), Colchicine (1.5 nM), vinblastine (6 nM), or paclitaxel (1.5 nM).
See also Figure S4.
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Chemistry & Biology 18,we have shown that the effects of UA62784 are additive or even
synergistic with other microtubule-targeting agents currently
used in clinics such as vinca alkaloids. These findings could
have positive outcomes for future treatment of cancers. Indeed,
UA62784 and one of its derivative, PC-046 are particularly cyto-
toxic (low nanomolar range) in human pancreatic cancer cell line
BxPC3 (Shaw et al., 2009).
UA62784 was initially described as an inhibitor of the mitotic
kinesin CENP-E at micromolar doses (Henderson et al., 2009)
but in our hands, this is not the case. The defects in spindle bipo-
larity observed by Henderson and colleagues after UA62784
treatment at nanomolar concentrations already suggested the
presence of other cellular targets. Furthermore, b-tubulin stain-
ing in Panc-1 cells showed that UA62784 treatment induces
microtubule depolymerization. Finally, a subsequent study per-
formed on UA62784 and on a library of 80 analogs, showed
that these diaryl oxazole compounds inhibit several protein
kinases at micromolar doses, but not kinesins (Shaw et al.,
2009). We therefore conclude that the original effects observed
upon treatment with low doses of UA62784 were misinterpreted
as the result of CENP-E inhibition. Indeed, the phenotype of
CENP-E gene knockout (Putkey et al., 2002) is very similar to
the one observed in Figure 5B (type I).
Strikingly, we observe a good correlation between the half-
maximal concentration of UA62784 required to inhibit tubulin
polymerization ( 82 nM), the dissociation constant of UA62784
from a/b tubulin ( 27 nM), and the half-maximal dose required
to inhibit the growth of HeLa cells ( 31 nM), which confirmed
the implication of the first binding mode of UA62784 to tubulin
in the inhibition. This could indicate that UA62784 kills cancer
cells mainly by enhancing tubulin depolymerization. However,
the multipolar spindles or mono-oriented chromosomes trapped
at the pole that we observed after 8 hr of drug treatment
suggests that UA62784 also suppresses microtubule dynamics,
like vinca alkaloids (Jordan and Kamath, 2007). Furthermore,
due to the high intracellular concentration of tubulin, MTs target-
ing drugs usually accumulate at higher concentrations in cells
over that in medium (Jordan and Kamath, 2007). Whether this
is also the case for UA62784 remains to be determined.
Structurally, UA62784 incorporates an oxazole core that
carries a fluorenone substituent at C-2 (Figure S5). A literature
survey shows that oxazole-based compounds (1–3) and fluore-
none derivatives (4, 5) bind tomicrotubules and act as antimitotic
agents (Oertel et al., 1992; Stefely et al., 2010; Wang et al.,
2002; Wipf et al., 2002). Notably, oxazoles of type 1, 3 exhibit
antitubulin and cytotoxic activity by binding to the colchicine
site with IC50 values in the micromolar range. The compounds
binding to the colchicine site inhibit formation of the Cys239
and Cys354 crosslink in b-tubulin and stimulate a GTPase
reaction uncoupled from microtubule assembly (Hamel, 1996).
A common structural motif in these compounds is the presence
of at least one and generally two oxygenated phenyl residues.
Guided by the structure of UA62784, we performed competition
experiments between UA62784 and [3H]-colchicine, which
revealed that UA62784 interacts with tubulin at or near the
colchicine-binding site. These data are further supported by
our preliminary docking experiments using the molecular
modeling program AUTODOCK 4.0 (Morris et al., 1998), which
revealed a molecular conformation of UA62784 within the631–641, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 637
A Experimental values of IG
50
 (nM)
Drugs UA62784 UA62784 UA62784 UA62784
(0 nM) (5 nM) (10 nM) (20 nM)
UA62784 31 ± 1
Nocodazole 35.8 ± 0.8 25.3 ± 1 10.1 ± 0.9 8.8 ± 0.2
Vinblastine 13.9 ± 0.2 10.9 ± 0.2 7.2 ± 0.2 3.7 ± 0.3
Paclitaxel 1.7 ± 0.002 1.7 ± 0.1 1.6 ± 0.1 0.9 ± 0.04
Doxorubicine 240 ± 8 240.2 ± 15 233.8 ± 10 218 ± 11
B
C Values of combination index (CI), interaction effect (IE) and probability of error (p)
)Mn 02( 48726AU)Mn 01( 48726AU)Mn 5( 48726AU
Drugs CI IE p CI IE p CI IE p
Nocodazole 0.86 ± 0.03 SS p<0.001 0.60 ± 0.02 S p<0.001 0.89 ± 0.006 SS p<0.001
Vinblastine 0.95 ± 0.02 NA p<0.001 0.84 ± 0.01 MS p<0.001 0.91 ± 0.003 NA p<0.001
Paclitaxel 1.16 ± 0.05 SA p<0.01 1.26 ± 0.05 MA p<0.01 1.18 ± 0.009 SA p<0.01
Doxorubicine 1.32 ± 0.07 MA p<0.01 1.61 ± 0.06 A p<0.01 2.14 ± 0.075 A p<0.01
S: Synergism, MS: Moderate Synergism; SS: Slight Synergism; NA: Nearly Additive
SA: Slight Antagonism; MA: Moderate Antagonism; A: Antagonism
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Figure 7. UA62784 Synergizes with Vinblastine or Nocodazole, but Antagonizes with Paclitaxel or Doxorubicine to Inhibit the Proliferation of
HeLa Cells
(A) Growth inhibition (IG50) of HeLa H2B-GFP cells was quantified by fluorescence using high content cell screening (Cellomics) at 0; 1; 2; 3; and 4 days after
treatment with a range of concentrations for the indicated drugs either alone, or in combination with 5 nM; 10 nM or 20 nM of UA62784.
(B) Isobolographic analysis of pharmacodynamic interactions between UA62784 and the indicated drugs. Plotting of the IG50 in experiments where UA62784 was
added in combination to the other indicated drugs, relative to theoretical additive lines (see Table S1) indicate synergy between UA62784 and nocodazole or
vinblastine, and antagonism between UA62784 and paclitaxel or doxorubicine.
(C) Values of the corresponding combination indexes (CI), interaction effect (IE) and probability of error (P-value) determined by t-criterion of Student for paired
data.
Error bars represent the standard deviation from three independent experiments.
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UA62784, A Cytotoxic Inhibitor of Microtubulescolchicine-binding site of b-tubulin notably closer to the podo-
phyllotoxin conformation (Ravelli et al., 2004). Furthermore, the
docking model revealed a potential H-bond formed with Thr-
179 and the carbonyl group of UA62784 (data not shown).
According to our results, UA62784 represents a novel antitubulin
chemotype and a potent inhibitor of tubulin polymerization.
Because of its structural simplicity compared with the well-
known vincas or taxanes and their potent cytotoxicity, UA62784
is a very attractive lead compound for further structural modifi-
cations and modeling investigations.
In this study, we have provided the first insight into the mech-
anism of anticancer activity by UA62784. Chemotherapies
usually consist of a few hours of treatment on a weekly basis,
the tumor therefore experiences only transient exposure to the
higher dose of drug. Since UA62784 perturbs the cell cycle
over a wide range of concentrations, it is likely to be an efficient
drug. The development of clinical drug resistance is a major
obstacle to cancer therapies, and metronomic chemotherapy
could be one way to overcome this issue (Pasquier et al.,638 Chemistry & Biology 18, 631–641, May 27, 2011 ª2011 Elsevier2010). Therefore, discovery of new chemotherapeutic drugs
and new combinations and schedules for cytostatic agents is
an important finding for cancer therapeutics. For example, the
use of haloperidol in combination with vinblastine reversed the
resistance of K562/VBL cells to vinblastine (Kataoka et al.,
2001) and the use of imatinib and nilotinib reversed MRP7-medi-
ated paclitaxel resistance (Shen et al., 2009). Having shown that
combination of UA62784with different drugs can lead to additive
or even synergistic effects is encouraging in pursuing that route,
provided that in vivo analysis will confirm efficacy in xenograft
mouse models.
SIGNIFICANCE
Microtubule-targeting agents remain themost efficient anti-
mitotics used in chemotherapies to treat cancer. In this
study, we showed that UA62784 directly targets tubulin via
the colchicine-binding site, and that it inhibits microtubule
polymerization at nanomolar doses in vitro and in vivo.Ltd All rights reserved
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UA62784, A Cytotoxic Inhibitor of MicrotubulesUA62784 severely damages the mitotic spindle, delays the
cell cycle in mitosis and promotes apoptosis. The antiproli-
ferative effect of UA62784 is additive, or even mildly syner-
gistic with vinca alkaloids, which could provide a strategy
to lower the doses, and thus to diminish drug-induced resis-
tance in tumor cells.
EXPERIMENTAL PROCEDURES
Antibodies and Drugs
All drugs were purchased from SIGMA. Polyclonal rabbit antibodies: antiphos-
pho histone H3 (Upstate Biotechnology); anti-BubR1 (Santa Cruz Biotech-
nology); anti-Pan-actin, anticleaved poly ADP ribose polymerase (PARP),
anticleaved Caspase-9, anti-caspase-3 are from Cell Signaling. Mouse
monoclonal antibodies: anti-MPM-2 (Upstate Biotechnology), anti-b-tubulin
(Sigma), anti-cyclin B1 (Santa Cruz Biotechnology). Secondary antibodies:
FITC-conjugated donkey anti-mouse and anti-rabbit antibodies are from Jack-
son ImmunoResearch. Goat anti-rabbit and anti-mouse HRP-conjugated anti-
bodies are from Promega.
Cloning and Purification of CENP-E Constructs
CENP-E-MD1-6His (aa 1-403) and CENP-E-MD2-6His (aa 1-473) were subcl-
oned by PCR into pET28a and pET21a-GFP respectively, using a full-length
human CENP-E construct as the template (a gift from Tim Yen, Pennsylvania).
The clones were validated by sequencing. For expression, the plasmids were
transformed into competent BL21(DE3) Escherichia coli host cells. The over-
night grown preculture was transferred into 1 l of 2xYTmedium (supplemented
with appropriate antibiotics) and grown at 37C until OD600 reached 0.6–1.0.
Expression was induced with 0.5 mM IPTG at 20C for 20–24 hr. The bacterial
pellets were frozen in liquid nitrogen, and stored at 80C. All subsequent
purification stepswere carried out at 4C.Cellswere resuspended in 20ml lysis
buffer (20 mM PIPES [pH 7.3], 200 mM NaCl, 2 mM MgCl2, 1 mM Na-EGTA,
10 mM imidazole, 0.2 mg/ml DNase, 0.5 mg/ml lyzozyme, and 1 mM PMSF),
incubated for 30 min, disrupted three times by sonication for 1 min and centri-
fuged for 30–40minat 19,000 rpm (Beckmann rotor JA-25.50). The supernatant
was loaded onto a 1 ml Ni-charged His-trap FF column (GE Healthcare) previ-
ously equilibrated in buffer A (20 mM PIPES [pH 7.3], 200 mM NaCl, 2 mM
MgCl2, 1 mM Na-EGTA, 10 mM imidazole). After washing with buffer A
(30 column volumes), the column was extensively washed with buffer A con-
taining 20 mM imidazole. The proteins were eluted with 20 column volumes
of buffer A containing 250 mM imidazole and collected in fractions of 1 ml.
The fractions containing CENP-E were concentrated using Amicon Ultra
concentrators (Millipore) to about 8 mg/ml and loaded onto a Superose 12
column equilibrated with buffer B (20 mM PIPES [pH 7.3], 200 mM NaCl,
2 mM MgCl2, 1 mM b-mercaptoethanol). Purified proteins were collected in
fractions of 0.5 ml, analyzed by SDS-PAGE, concentrated to 3–6 mg/ml as
described above, aliquoted, frozen in liquid nitrogen and stored at 80C.
ATPase Activities
All enzymatic reactions were performed at room temperature using a 96-well
Polarstar photometer at a final volume of 100 ml per well. Steady-state
ATPase rates were measured using the pyruvate kinase/lactate dehydroge-
nase-linked assay in buffer A25A (25 mM potassium ACES [pH 6.9], 2 mM
magnesium acetate, 2 mM Na-EGTA, 0.1 mM Na-EDTA, 1 mM b-mercaptoe-
thanol supplemented with 1 mM MgATP; 2 mM PEP; 0.25 mM NADH;
3–10 mg/ml pyruvate kinase; 3 mg/ml lactate dehydrogenase and 8 mM taxol).
In the presence of taxol-stabilizedmicrotubules, 50–80 nMof CENP-E proteins
were used for the assay. In the absence of microtubules, the basal ATPase
activity was measured using 2–4 mM CENP-E. For optimal inhibitor solubility,
the assays were done in the presence of up to 5% DMSO. The data were
analyzed using Kaleidagraph 3.0 (Synergy Software, Reading, PA) and Micro-
soft Excel.
Microtubule Polymerization Assays
Porcine tubulin was prepared as described (Espeut et al., 2008). Tubulin poly-
merization assayswere carried out at 37C inPEMbuffer (100mMPIPES, 1mM
Na-EGTA, and 1 mM MgCl2 [pH 6.9]) by mixing 60 mM of tubulin, 4% DMSOChemistry & Biology 18,and the indicated concentrations of drugs, in a total volume of 50 ml. For micro-
tubule-pelleting assays, the mixtures were centrifuged at 50,000 3 g for
10 min, and the pellet or supernatant fractions were analyzed by SDS-PAGE.
For microtubule-turbidity assays, absorbance at 340 nm was measured in
96-well plates with a Polarstar photometer (BMG, Labtech) every 7 sec.
Steady-State Fluorescence Experiments
Fluorescence experiments were performed on a SPEX-PTI spectrofluorometer
at 25C in PEM buffer supplemented with 10 mM CaCl2. Intrinsic tryptophan
fluorescence of tubulin heterodimers was excited at 290 nm with a 2 nm
slot, and emission spectra were recorded from 300 to 600 nm, with a spectral
band-pass of 8 nm. A fixed concentration of tubulin a/b dimers (0.3 mM) was
titrated with increasing drug concentrations from 15 nM to 75 mM. All measure-
ments were corrected for the dilution, and data were fitted (Grafit software,
Erithacus) with quadratic equations testing for the existence of one or two
binding sites (Pelicano et al., 1997). For the four drugs tested, the best fit
was obtained with the ‘‘two binding sites’’ equation:
F=Fini  ðF1Þ

ðKd1 + L0 +E0Þ 
h
ðKd1 + L0 +E0Þ24 E0 L0
i
1=2

ð2 E0Þ
 ðF2ÞfL0=ðKd2 + L0Þg:
Fini is the fluorescence intensity at the start of the titration, F1 and F2 are the
fluorescence-quenching values induced by the first and the second binding
respectively, E0 is the total concentration of protein, L0 the total concentration
of ligand, and Kd1 and Kd2 the dissociation constant for the first and the second
binding sites of the drug onto tubulin.
[3H]-Colchicine Tubulin-Binding Assay
Colchicine tubulin-binding assays were done using the centrifugal gel filtration
method (Koizumi et al., 2004) with minor modifications. Twelve microliter
aliquots of 2 mM purified tubulin in PEM buffer supplemented with 10 mM
CaCl2 were incubated with 0.13 mM of [
3H]-colchicine (1 mCi/ml; specific
activity, 75.5 Ci/mmol; Perkin-Elmer, Melbourne, Australia) in the absence or
presence of various drugs for 20 min at room temperature. After the incuba-
tion, 10 ml of each sample was loaded onto a 75 ml spin column Zeba
Micro Desalt Spin Columns (PierceBiotechnology, Inc.) and centrifuged at
1000 3 g for 2 min to obtain the tubulin fraction. After the addition of the
scintillation fluid, the radioactivity of [3H]-colchicine-bound tubulin was
measured using a LS6500 scintillation counter (Beckman Coulter).
Cell Culture and Flow Cytometry
HeLa and HeLa-H2B-GFP cells were grown in DMEMmedium (Invitrogen) and
H358 cells were cultivated in RPMI 1640 medium (Invitrogen). Cell cultures
were supplemented with 2 mM L-glutamine, 1% penicilin/streptomycin and
10% FBS. All cell lines were maintained in a humid incubator at 37C in 5%
CO2. Cells at 60%–70% of confluence were treated with UA62784 for 12,
24, and 48 hr and subsequently collected by pooling together the nonattached
and attached cells. After washing in PBS, cells were fixed with methanol for
20 min at 20C. To estimate the percent of cells that entered mitosis, cells
were incubated for 1 hr at 37C with anti-MPM2 antibody (1:500). After two
washes, the cells were stained with FITC-conjugated anti-mouse antibody
(1:250). The suspension of stained cells was analyzed by flow cytometry
(Becton Dickinson), using CellQuest software. For each sample 10,000 events
were collected and aggregated cells were gated out.
Western Blot
HeLa cells were harvested, washed with PBS and subsequently lysed in buffer
(50 mM Tris [pH 7.4], containing 250 mM NaCl, 0.1% NP-40, 0.1 mM PMSF,
aprotinine at 10 mg/ml, leupeptine at 10 mg/ml, and 100 mM NaF) for
30 min on ice. Then, the cell lysate was centrifuged for 10 min at 13 000 rpm
and the concentration of soluble proteins in supernatant was measured by
the Bradford method. Equal amount of proteins (30 mg) were resolved by
SDS/PAGE, electro-transferred onto nitrocellulose membrane and treated
overnight with the appropriate primary antibody diluted 1:1000. Then the
membrane were quickly washed and incubated for 1 hr at room temperature
with the secondary HRP-conjugated anti-rabbit or anti-mouse antibody.
Finally, the membranes were revealed with ECL (Pierce).631–641, May 27, 2011 ª2011 Elsevier Ltd All rights reserved 639
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For immunofluorescence, cells were grown on poly-D-lysine–coated cover-
slips placed in 60 cm2 Petri dishes at least 24–36 hr before drug addition.
When cells reached 50%–70% confluence the medium was replaced with
a fresh one supplemented with UA62784. After exposure to UA62784, cells
were fixed in 2% paraformaldehyde in PBS for 20 min at 37C and treated
with anti-b-tubulin antibody (1:400) and anti-g-tubulin (1:200) for 1 hr at
37C. Cells were washed three times in PBS for 10 min at room temperature,
and subsequently incubated with a FITC-conjugated donkey anti-mouse
or Alexa 633 conjugated anti-rabbit antibodies (1:1000) for 30 min at 37C.
After three PBS washes at room temperature, cells were counterstained
with PI at 0.5 mg/ml. Finally, the coverslips were washed in PBS three times
for 5 min, and mounted on microscopic slides with Mowiol. Images were
captured with a Zeiss AxioimagerZ1 motorized microscope, restored by
the deconvolution program Huygens Remote Manager (HMR) and analyzed
using the Metamorph software or by LSM-510 META Zeiss confocal micro-
scope and analyzed using the ImageJ software. For time-lapse video micro-
scopy, we used nonsynchronized HeLa cells stably expressing Histone-H2B
fused to GFP or HeLa cells stably expressing tubulin fused to GFP. Cells
were filmed with a Zeiss Axiovert 200M inverted microscope or Spining disc
Perkin Elmer microscope equipped with an incubation chamber at 37C in
5% CO2 and controlled by Metamorph 7.1 software (Molecular Devices,
Sunnyvale, CA). Differential interference contrast (DIC) and GFP fluorescence
images were taken every 10 min for 72 hr to analyze the proliferation dynamic,
or every 2–5 min to visualize the drug effect on interphase and metaphase
microtubules.
High-Content Cell Screening
HeLa-H2B-GFP were grown on 96-well plates and imaged every 24 hr during
4 days using a Cellomics Arrayscan VTI Live. The amount of live cells in three
different fields was calculated for each well. The rate of cell proliferation was
estimated as the percentage of live cells compared to control. The proliferation
assay was performed in duplicate in three independent experiments. Doses of
single drugs used: UA62784 (0; 10; 20; 40; 80; 160 nM), nocodazole (0; 15; 30;
60; 120; 240 nM), vinblastine (0; 1; 2; 4; 8; 16 nM), paclitaxel (0; 0.5; 1; 2; 4;
8 nM), and doxorubicin (0; 125; 250; 500; 1000; 2000 nM). The statistical
significance of the difference between the control and treated groups was
determined by t-criterion of Student. P values %0.01 were considered to be
statistically significant.
Drug Combinations Analysis
Isobolograms and combination indexes (CI) were determined from the high
content screening data after 96 hr. The concentration of compound that
caused a 50% growth inhibition (IG50) was determined for UA62784, nocoda-
zole, vinblastine, paclitaxel, and doxorubicin. The isobolograms were gener-
ated by dually combining the tested drugs to 5, 10, or 20 nM of UA62784
under the following ratio: 5:1, 2:1 and 1:2, respectively. The CI for UA62784
with the drugs acting via a similar mechanism (mutually exclusive) such as
nocodazole, vinblastine and paclitaxel was calculated according to the
following equation:
Cl= ðDÞ1=ðDxÞ1 + ðDÞ2=ðDxÞ2;
while the CI for UA62784 with doxorubicine, a drug acting via a totally indepen-
dent mechanism (mutually nonexclusive) was calculated with the following
equation:
Cl= ðDÞ1=ðDxÞ1 + ðDÞ2=ðDxÞ2 + ðDÞ1ðDÞ2=ðDxÞ1ðDxÞ2;
where (D)1 and (D)2 are the IG50 with the combination of drugs 1 and 2, and
(Dx)1 and (Dx)2 are the IG50 of drugs 1 and 2 as single compounds. CI value =
1 indicates an additive effect, CI < 1 suggests synergism and CI > 1 suggests
antagonism. Degrees of synergism or antagonism were determined using the
CI ranges previously described (Chou, 2006).
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